SK pharmteco highlighted manufacturing best practices aimed at enabling in vivo lentiviral therapies, focusing on purity, scalability, and clinical readiness. In a GEN Podcast, SK pharmteco executives discussed how the shift from ex vivo tools to in vivo platforms increases demands for higher doses, tighter impurity control, and more consistent batch performance. The discussion emphasized designing workflows that support larger scale while maintaining product quality attributes and reproducibility—requirements that become more stringent as vector doses rise. The speakers also framed manufacturing as a systems problem: impurity management, consistency, and documentation need to keep pace with evolving clinical expectations. For developers, the key takeaway is that lentiviral programs targeting in vivo use must treat manufacturing data packages as core clinical infrastructure, not downstream compliance.